MetaCap

Corbus Pharmaceuticals (CRBP) vs OS Therapies (OSTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OS Therapies (OSTX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 53.0% versus a loss of 82.8%. Corbus Pharmaceuticals is the larger company by market cap ($42.4 million vs $42.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRBP-82.85%OSTX-53.04%
+37%-26%-89%
Nov 21, 20251 yearNov 20, 2026
CRBP-96.36%OSTX-79.92%
+35%-34%-103%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRBP versus OSTX key metrics
MetricCRBPOSTX
Share price$2.06$0.803
Market cap$42.45M$42.00M
1-day change-15.40%-2.12%
YTD return-74.69%-42.64%
1-year return-82.85%-53.04%
5-year return-92.23%—
Forward P/E—2.29
EPS (TTM)$-6.04$-1.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-78.54M$-28.75M
52-week high$12.88$2.25
52-week low$2.01$0.58
Distance from 52-week high-84.01%-64.31%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1551.94%+958.53%
Average volume1.11M722.66K
Shares outstanding20.61M52.30M
Employees364
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OSTX has outperformed CRBP by 29.8 percentage points over the past year.

About Corbus Pharmaceuticals

CRBP stock →

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

CRBP vs OSTX FAQ

Which is bigger, Corbus Pharmaceuticals or OS Therapies?

Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $42.45M compared with $42.00M for OS Therapies (OSTX).

Which stock has performed better over the past year, CRBP or OSTX?

OSTX returned -53.04% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.

Are Corbus Pharmaceuticals and OS Therapies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons